<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shao F</submitter><funding>National Basic Research Program of China</funding><funding>Beijing Municipal Science and Technology Commission</funding><pagination>54</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6775656</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Cancer cells reprogram metabolism for proliferation. Phosphoglycerate kinase 1 (PGK1), as a glycolytic enzyme and newly identified protein kinase, coordinates glycolysis and mitochondrial metabolism. However, the clinical significance of PGK1 expression and function in cancer progression is unclear. Here, we investigated the relationship between the progression and prognosis of multiple cancer types and PGK1 expression and its function in the mitochondrial metabolism regulation.&lt;h4>Methods&lt;/h4>We performed pan-cancer analyses of PGK1 mRNA level and DNA methylation in 11,908 tumor tissues and 1582 paired normal tissues across 34 cancer types in The Cancer Genome Atlas datasets. Using specific antibodies against PGK1 S203 and PDHK1 T338 phosphorylation, we performed immuno</pubmed_abstract><journal>Cancer communications (London, England)</journal><pubmed_title>Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis.</pubmed_title><pmcid>PMC6775656</pmcid><funding_grant_id>Z181100001918002</funding_grant_id><funding_grant_id>2018YFC1312100</funding_grant_id><funding_grant_id>2017YFC1308702</funding_grant_id><funding_grant_id>Z181100006218032</funding_grant_id><funding_grant_id>2017YFC1311000</funding_grant_id><pubmed_authors>Shao F</pubmed_authors><pubmed_authors>Yang X</pubmed_authors><pubmed_authors>Shi S</pubmed_authors><pubmed_authors>He J</pubmed_authors><pubmed_authors>Feng X</pubmed_authors><pubmed_authors>Guo W</pubmed_authors><pubmed_authors>Xue Q</pubmed_authors><pubmed_authors>Lu Z</pubmed_authors><pubmed_authors>Gao Y</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Gao S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis.</name><description>&lt;h4>Background&lt;/h4>Cancer cells reprogram metabolism for proliferation. Phosphoglycerate kinase 1 (PGK1), as a glycolytic enzyme and newly identified protein kinase, coordinates glycolysis and mitochondrial metabolism. However, the clinical significance of PGK1 expression and function in cancer progression is unclear. Here, we investigated the relationship between the progression and prognosis of multiple cancer types and PGK1 expression and its function in the mitochondrial metabolism regulation.&lt;h4>Methods&lt;/h4>We performed pan-cancer analyses of PGK1 mRNA level and DNA methylation in 11,908 tumor tissues and 1582 paired normal tissues across 34 cancer types in The Cancer Genome Atlas datasets. Using specific antibodies against PGK1 S203 and PDHK1 T338 phosphorylation, we performed immuno</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Oct</publication><modification>2026-04-16T13:21:02.537Z</modification><creation>2019-10-16T07:06:37Z</creation></dates><accession>S-EPMC6775656</accession><cross_references><pubmed>31578148</pubmed><doi>10.1186/s40880-019-0401-9</doi></cross_references></HashMap>